AIM: To examine whether poly-unsaturated fatty acid(PUFA) therapy is beneficial for improving nonalcoholic steatohepatitis(NASH).METHODS: In total, 78 patients pathologically diagnosed with NASH were enrolled and were...AIM: To examine whether poly-unsaturated fatty acid(PUFA) therapy is beneficial for improving nonalcoholic steatohepatitis(NASH).METHODS: In total, 78 patients pathologically diagnosed with NASH were enrolled and were randomly assigned into the control group and the PUFA therapy group(added 50 mL PUFA with 1:1 ratio of EHA and DHA into daily diet). At the initial analysis and after 6mo of PUFA therapy, parameters of interest including liver enzymes, lipid profiles, markers of inflammation and oxidation, and histological changes were evaluated and compared between these two groups.RESULTS: At the initial analysis, in patients with NASH, serum levels of alanine aminotransferase(ALT)and aspartase aminotransferase(AST) were slightly elevated. Triglyceride(TG), total cholesterol(TC) and low-density lipoprotein cholesterol levels, markers of systemic inflammation [C-reactive protein(CRP)] and oxidation [malondialdehyde(MDA)], as well as fibrosis parameters of type Ⅳ collagen and pro-collagen typeⅢ pro-peptide were also increased beyond the normal range. Six months later, ALT and AST levels were significantly reduced in the PUFA group compared with the control group. In addition, serum levels of TG and TC, CRP and MDA, and type Ⅳ collagen and procollagen type Ⅲ pro-peptide were also simultaneously and significantly reduced. Of note, histological evaluation showed that steatosis grade, necroinflammatory grade, fibrosis stage, and ballooning score were all profoundly improved in comparison to the control group, strongly suggesting that increased PUFA consumption was a potential way to offset NASH progression.CONCLUSION: Increased PUFA consumption is a potential promising approach for NASH prevention and reversal.展开更多
文摘AIM: To examine whether poly-unsaturated fatty acid(PUFA) therapy is beneficial for improving nonalcoholic steatohepatitis(NASH).METHODS: In total, 78 patients pathologically diagnosed with NASH were enrolled and were randomly assigned into the control group and the PUFA therapy group(added 50 mL PUFA with 1:1 ratio of EHA and DHA into daily diet). At the initial analysis and after 6mo of PUFA therapy, parameters of interest including liver enzymes, lipid profiles, markers of inflammation and oxidation, and histological changes were evaluated and compared between these two groups.RESULTS: At the initial analysis, in patients with NASH, serum levels of alanine aminotransferase(ALT)and aspartase aminotransferase(AST) were slightly elevated. Triglyceride(TG), total cholesterol(TC) and low-density lipoprotein cholesterol levels, markers of systemic inflammation [C-reactive protein(CRP)] and oxidation [malondialdehyde(MDA)], as well as fibrosis parameters of type Ⅳ collagen and pro-collagen typeⅢ pro-peptide were also increased beyond the normal range. Six months later, ALT and AST levels were significantly reduced in the PUFA group compared with the control group. In addition, serum levels of TG and TC, CRP and MDA, and type Ⅳ collagen and procollagen type Ⅲ pro-peptide were also simultaneously and significantly reduced. Of note, histological evaluation showed that steatosis grade, necroinflammatory grade, fibrosis stage, and ballooning score were all profoundly improved in comparison to the control group, strongly suggesting that increased PUFA consumption was a potential way to offset NASH progression.CONCLUSION: Increased PUFA consumption is a potential promising approach for NASH prevention and reversal.
